ASLAN Pharmaceuticals Limited ASLN
Set alert
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 1.70M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -0.03
- Beta
- 1.40
- Short ratio
- 1.85
- Inst. own
- 13.21%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 9, 2024
- 50-d avg
- 1.07
- 200-d avg
- 3.48
- 1y target
- 72.00
News
7 months ago defenseworld.net
Critical Contrast: ASLAN Pharmaceuticals (NASDAQ:ASLN) vs. Argos Therapeutics (OTCMKTS:ARGSQ)
Profitability This table compares Argos Therapeutics and ASLAN Pharmaceuticals' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Argos Therapeutics…
7 months ago defenseworld.net
Analyzing ASLAN Pharmaceuticals (NASDAQ:ASLN) & CannTrust (OTCMKTS:CNTTF)
Valuation and Earnings This table compares CannTrust and ASLAN Pharmaceuticals"s gross revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share…
-
2 years ago benzinga.com
Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
-
2 years ago benzinga.com
Nasdaq Dips 300 Points; Johnson & Johnson Earnings Top Estimates
Nasdaq Dips 300 Points; Johnson & Johnson Earnings Top Estimates
2 years ago globenewswire.com
ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary Liquidation
SAN MATEO, Calif. and SINGAPORE, July 17, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN” or the “Company”), a clinical-stage, immunology-focused biopharmaceutical company developing…
-
2 years ago benzinga.com
Why SolarEdge Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Why SolarEdge Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
2 years ago globenewswire.com
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to Appeal
SAN MATEO, Calif. and SINGAPORE, July 15, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN” or the “Company”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company…
2 years ago zacks.com
All You Need to Know About ASLAN Pharmaceuticals (ASLN) Rating Upgrade to Buy
ASLAN Pharmaceuticals (ASLN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2 years ago zacks.com
Here's Why ASLAN Pharmaceuticals (ASLN) Could be Great Choice for a Bottom Fisher
ASLAN Pharmaceuticals (ASLN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions…
2 years ago globenewswire.com
ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International Conference
SAN MATEO, Calif. and SINGAPORE, May 21, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments…
2 years ago globenewswire.com
ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
SAN MATEO, Calif. and SINGAPORE, May 09, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments…
2 years ago globenewswire.com
ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event
SAN MATEO, Calif. and SINGAPORE, May 07, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments…
2 years ago globenewswire.com
ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics
SAN MATEO, Calif. and SINGAPORE, May 02, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments…
2 years ago globenewswire.com
ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab
SAN MATEO, Calif. and SINGAPORE, April 30, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative…
2 years ago globenewswire.com
ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
Interim readout of 22 patients shows unprecedented efficacy data compared to prior atopic dermatitis (AD) studies with biologics: 60.0% of dupilumab -experienced AD patients treated with 400mg…
2 years ago globenewswire.com
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice
SAN MATEO, Calif. and SINGAPORE, April 19, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative…
2 years ago globenewswire.com
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
SAN MATEO, Calif. and SINGAPORE, April 12, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative…
2 years ago zacks.com
Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year?
Here is how ASLAN Pharmaceuticals Ltd. (ASLN) and Assembly Biosciences (ASMB) have performed compared to their sector so far this year.
2 years ago globenewswire.com
Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders
SAN MATEO, Calif. and SINGAPORE, March 27, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceutical (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative…
2 years ago globenewswire.com
ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering
SAN MATEO, Calif. and SINGAPORE, March 12, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative…
2 years ago zacks.com
ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study
ASLAN (ASLN) rises on upbeat initial data from a phase II study of eblasakimab in patients with eczema, who have previously been treated with Dupixent but did not achieve an adequate response.
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
2 years ago globenewswire.com
ASLAN Pharmaceuticals Receives Favorable Opinion From the European Patent Office on Composition of Matter Patent Application for Farudodstat
SAN MATEO, Calif. and SINGAPORE, Feb. 29, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative…
2 years ago globenewswire.com
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
SAN MATEO, Calif. and SINGAPORE, Jan. 08, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN) ("ASLAN" or the "Company"), announced today that on January 5, 2024, it received a written…
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 369 companies hit new 52-week lows.
-
3 years ago benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For May 31, 2023
Benzinga's Top Ratings Upgrades, Downgrades For May 31, 2023
-
4 years ago benzinga.com
Why Nuwellis Surged Over 121%; Here Are 66 Biggest Movers From Yesterday
Gainers
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
Monday's session saw 84 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
During Friday's trading, 69 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 215 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 807 companies reached new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 1043 companies hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's trading, 435 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
On Monday, 721 companies achieved new lows for the year.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 160 companies hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 242 companies hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's morning trading, 400 companies set new 52-week lows.
-
5 years ago benzinga.com
31 Stocks Moving In Monday's Mid-Day Session
Gainers Red Cat Holdings, Inc. (NASDAQ: RCAT) shares jumped 54.1% to $3.6998 after the company said its subsidiary, Skypersonic, Inc, won a five-year contract from NASA to provide drone and rover…
-
5 years ago benzinga.com
20 Stocks Moving in Monday's Pre-Market Session
Gainers Puhui Wealth Investment Management Co., Ltd. (NASDAQ: PHCF) rose 49% to $3.65 in pre-market trading.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Monday
During Monday's morning session, 230 companies made new 52-week highs.
-
5 years ago benzinga.com
70 Biggest Movers From Yesterday
Gainers Pandion Therapeutics, Inc. (NASDAQ: PAND) shares surged 133.4% to close at $59.81 on Thursday after the company announced it will be acquired by Merck for $60 per share in cash.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Thursday
Before 10 a.m. ET Thursday, 371 stocks hit new 52-week highs.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Wednesday
This morning 533 companies reached new 52-week highs.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Tuesday
On Tuesday morning, 172 companies achieved new highs for the year.
-
6 years ago benzinga.com
64 Biggest Movers From Friday
Gainers Hertz Global Holdings (NYSE: HTZ) stock climbed 142.7% to close at $2.50 on Friday following news the company secured $1.65 billion in debtor-in-possession financing commitments.
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Monday
Stocks That Hit 52-Week Highs On Monday
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Friday
Stocks That Hit 52-Week Highs On Friday